Symbiotec Pharmalab, a leading API manufacturer, is planning an IPO. The company targets a valuation of about $1 billion. The IPO aims to raise ₹2,000-2,500 crore. Nomura, JM Financial, and Motilal Oswal are the lead managers. The IPO will offer a partial exit to private equity investors. MOPE and InvAscent currently hold a significant stake in Symbiotec.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets